Skip to main content
. 2020 Feb 3;117(7):3728–3737. doi: 10.1073/pnas.1919764117

Fig. 3.

Fig. 3.

Comparison of model predictions with experimental data reported by Huang et al. (36) (A), Zheng et al. (19) (B), and Shigeta et al. (49) (C). The x-axis shows the various treatment groups included in the experimental studies: DC101, an anti-VEGF antibody; anti–PD-1, a PD-1 blocker; and anti–CTLA-4, a CTLA-4 blocker.